In October 2014 Chantest was acquired by Charles River Laboratories. ChanTest, Inc. is an Ion Channel Platform Organization specializing in preclinical safety testing for drugs that may have unintended cardiac side effects such as QT prolongation and the malignant arrhythmia, torsade de pointes. ChanTest has developed a comprhensive library of validated human ion channel-expressing cell lines to serve all the ion channel needs of its pharmaceutical and biotech customers. Services range from early functional screens for profiling drug candidates or ranking within profiles during the drug-discovery process to a complete set of in vitro GLP service products for cardiac risk assessment. ChanTest works in partnership with customers to speed the drug-development process, save time and money, and ultimately ââ¬â to help make better, safer dr
